[Long-term danazol therapy for hereditary angioedema].
Three patients with hereditary angio-oedema, two men of 19 and 35 years and a woman of 69 years, have been treated for 10 years with danazol, an androgen preparation with diminished androgenic effects. The 19-year-old man started taking it at the age of nine years and continued throughout puberty. Maintenance therapy with 200 mg twice a week, together with occasional booster doses of 200 mg daily, started at the age of 16 years and given when required cut the frequency of attacks from one a week to roughly six a year and greatly reduced their severity. Sexual maturation was entirely normal. The 35-year-old man, who had previously had three severe attacks a week, became symptom-free on a dose of 200 mg four or five times a week. During treatment he fathered a healthy child. The 69-year-old woman had had attacks every four weeks after the menopause, but obtained complete relief from a dose of 200 mg six times weekly. C1-Esterase inhibitor--originally depressed to around 30% of normal in all these patients--rose to about 50% during treatment. Endocrine, metabolic and toxic side-effects were minimal.
Höpfl
R
R
Klinik für Dermatologie und Venerologie, Universität Innsbruck.
Schwarz
S
S
Fritsch
P
P
Hintner
H
H
D000328:Adult; D000368:Aged; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005298:Fertility; D006801:Humans; D008297:Male; D011245:Pregnadienes / Q000627:therapeutic use*; D012741:Sexual Maturation
D011245:Pregnadienes; D003613:Danazol
Danazol-Langzeittherapie bei hereditärem Angioödem.